My sense is that most folks were of the understanding that the company's work with Moffitt was focused on PV-10's mechanism of action. PV-10's MOA, of targeting and how it kills cancerous cells, is well established.
We know of PV-10's great success in treating tumors at the local level. What is of course very intriguing, and what Dr. Ross highlighted, both in general and specifically about PV-10, is the compound's bystander effect and systemic benefit.
So, Moffitt isn't working just on PV-10's MOA. Rather, their work is on the mechanism of immunologic response ("MOIR"), which goes to the systemic benefit of PV-10. MOA, in the context of Provectus, is a multi-step process, with the chemoablation of the cancer cells followed by the immunotherapeutic effects of the ablation, which is the bystander response or immune-mediated response.
Think of it this way: Lots of companies work on studies and put of communications regarding the MOA of their respective compounds. Management has checked this box at the local level. Together with Moffitt -- and recall that two immuno-studies already have been completed, with another in process, and more planned for next year -- the curiosity about PV-10 and subsequent demand for information is about the MOA at the remote or distant level.